Le Lézard
Classified in: Health
Subject: ACC

DSM - Repurchase of Shares (6 ? 12 April 2018)


HEERLEN, Netherlands, April 13, 2018 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials, has repurchased 88,350 of its own shares in the period from 6 April 2018 up to and including 12 April 2018 at an average price of ?81.74. This is in accordance with the repurchase, covering commitments under share based compensation plans and for stock dividends, announced on 19 March 2018. The consideration of this repurchase was ?7.2 million. 

     (Logo: https://mma.prnewswire.com/media/657851/DSM_Logo.jpg )

The total number of shares repurchased under this program to date is 500,000 shares for a total consideration of ?40.1 million.

For more detailed information see 'Daily transaction details 1.6m Share Repurchase Program announced 19 Mar 2018'.

DSM - Bright Science. Brighter Living.tm 

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Or find us on:

Facebook:  https://www.facebook.com/dsmcompany

Twitter:  https://www.twitter.com/dsm

LinkedIn:  https://www.linkedin.com/company/3108

YouTube:  https://www.youtube.com/user/dsmcompany

PDF:  https://mma.prnewswire.com/media/676609/Royal_DSM.pdf

 

For more information:  

DSM Media Relations
Lieke de Jong
tel. +31-(0)-45-578-2421
e-mail [email protected]

DSM Investor Relations
Dave Huizing
tel. +31-(0)-45-5782864
e-mail [email protected]


These press releases may also interest you

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...

at 08:00
Citius Pharmaceuticals Inc. ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...

at 08:00
Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami, sponsored by PrecisCa and the Community Oncology Alliance...

at 08:00
Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation at two prestigious medical conferences: the American...



News published on and distributed by: